What was recalled
This page synthesizes the conditionally essential framework for glycine in commercial pet food. Glycine (chemical formula C2H5NO2, with a single hydrogen as the side chain) is the simplest amino acid and the only proteinogenic amino acid that is achiral (no L- versus D-enantiomer distinction because the alpha-carbon does not have four different substituents). Glycine is traditionally classified as non-essential in mammalian nutrition because the body can synthesize it from serine via serine hydroxymethyltransferase (the vitamin-B6-dependent enzyme that interconverts serine and glycine) and from threonine via threonine aldolase (with species-specific pathway activity). The endogenous synthesis pathway is therefore intact and functional in dogs and cats under normal physiologic conditions. The conditional-essentiality framework emerges from the recognition that glycine synthesis capacity has finite kinetics and dietary requirement can exceed endogenous synthesis capacity during high glycine demand states.
The high-demand contexts for glycine include: glutathione (GSH) synthesis (the primary intracellular antioxidant tripeptide of glycine, glutamate, cysteine; consumed in detoxification, anti-oxidant defense, and conjugation reactions; turnover increases dramatically during oxidative stress, chemotherapy, toxin exposure, and chronic disease), collagen synthesis (collagen is approximately 33% glycine residues by amino acid composition, the highest glycine concentration of any major protein; demand increases during wound healing, growth, exercise-induced collagen turnover, and post-surgical recovery), bile salt synthesis (primary bile salts in dogs and cats are predominantly glycine-conjugated — glycocholic acid and glycochenodeoxycholic acid), heme synthesis (delta-aminolevulinate is synthesized from glycine and succinyl-CoA in the first committed step of heme biosynthesis), creatine synthesis (creatine biosynthesis uses glycine + arginine + methionine; relevant for muscle function and exercise capacity), renal-detoxification of hippurate (glycine conjugation of benzoic-acid derivatives in renal tissue), and porphyrin synthesis generally.
The commercial pet food framework for glycine adequacy has been shaped by the absence of AAFCO minimum specification. AAFCO Nutrient Profiles specify minimums for the nine canine essential amino acids plus methionine-cystine pair, and for cats the ten essential amino acids plus taurine (the obligate-carnivore-essential covered separately on our synthetic taurine controversy page). Glycine is treated as supplied by the protein anchor without specific minimum because endogenous synthesis is assumed adequate for routine maintenance. The conditional-essentiality framework challenges this assumption for specific physiologic stress contexts. Research by Wolfgang Bauer at UC Davis and others on glycine and other "non-essential" amino acids has highlighted the structural framework, with growing recognition that glycine adequacy beyond endogenous synthesis capacity may matter in renal disease, hepatic disease, chronic inflammation, and recovery contexts. The marketing-claim landscape has tracked this scientific evolution through the rise of bone broth as a pet food and supplement ingredient, with bone broth marketing claims often emphasizing the glycine, proline, and hydroxyproline content of collagen-derived gelatin.
Why it was recalled
The structural concern has three layers. Layer one — AAFCO does not specify glycine minimum: the absence of an AAFCO minimum means that pet food formulations are not directly screened for glycine adequacy beyond the implicit adequacy assumed from total protein content. A formulation using high-quality muscle meat as the protein anchor will deliver substantial glycine (4-7% of protein content) and is unlikely to face glycine inadequacy under routine physiologic conditions. A formulation using plant protein concentrates (soybean meal, pea protein) as the protein anchor will deliver lower glycine (3-5% of protein content) and may face glycine inadequacy under physiologic stress conditions where demand exceeds endogenous synthesis capacity. The structural lever for glycine adequacy in plant-protein-anchored formulations is collagen-rich ingredient inclusion (chicken paws, beef bone meal, bovine collagen, gelatin) or specific supplemental glycine premix; current commercial practice rarely targets either.
Layer two — conditionally essential status in chronic disease contexts: the populations where glycine adequacy is most likely to matter clinically are pets with chronic kidney disease (impaired hippurate excretion, elevated oxidative stress, elevated glutathione demand), hepatic disease (impaired bile salt synthesis, elevated detoxification demand, impaired endogenous synthesis), post-surgical recovery (elevated collagen synthesis demand for tissue repair), chronic inflammation including inflammatory bowel disease and chronic dermatitis (elevated oxidative stress, elevated glutathione demand), chemotherapy patients (elevated detoxification demand, elevated glutathione consumption), and senior pets with chronic comorbidity. The clinical context is well-developed in human nutrition literature but only partially translated to companion-animal practice as of mid-2020s. Veterinary therapeutic diets for chronic kidney disease and chronic hepatic disease typically have higher-than-baseline glycine inclusion through animal-protein anchor selection, but the formulation rationale is rarely explicit on label.
Layer three — bone broth marketing claims tie to glycine but with mixed evidence: the rise of bone broth as a pet food and supplement ingredient has been accompanied by marketing claims emphasizing the glycine, proline, and hydroxyproline content of collagen-derived gelatin. The marketing claims often cross into therapeutic territory (joint support, digestive support, immune support) where the bone broth glycine contribution may or may not deliver the claimed effect. Bone broth does deliver substantial glycine in absolute terms (a typical homemade bone broth contains 1-3 g/L glycine depending on collagen-tissue inclusion and cook time), but the contribution as a fraction of total dietary glycine depends on bone broth volume relative to total meal intake. Pets eating a standard commercial diet plus modest bone broth supplementation may receive a small percentage incremental glycine, while pets on a bone-broth-anchored homemade diet face the structural inadequacy concerns documented in our calcium phosphorus growth diet, AAFCO substantiation method, and raw meaty bones feeding framework pages. Bone broth as a complement to a balanced diet is reasonable; bone broth as an anchor of an unbalanced diet is risky.
Health risks for your pet
Clinical glycine deficiency in commercial-fed dogs and cats on AAFCO-compliant diets is rarely documented at the population level because endogenous synthesis covers requirements adequately under routine physiologic conditions. The conditional-essentiality framework suggests that subclinical glycine inadequacy may exist in pets with chronic disease, post-surgical recovery, chronic inflammation, and senior pets with multiple comorbidities, but the clinical significance of subclinical inadequacy is not well-characterized in companion animals as of mid-2020s. The structural concern is that pets in these high-demand contexts may benefit from collagen-anchored or glycine-rich diet selection (or specific veterinary therapeutic diets where glycine adequacy is implicitly addressed through animal-protein anchor selection), but the absence of AAFCO minimum specification means that diet selection on glycine grounds requires brand-customer-service inquiry or specialty-formulation selection.
Glycine excess from dietary sources or supplementation is uncommon and generally well-tolerated. Pharmacologic-dose glycine supplementation (typically 3-9 g/day in humans, scaled for companion animals) has been studied for sleep quality, glucose tolerance, and inflammatory marker modulation with mixed human evidence and limited companion-animal evidence. Routine over-the-counter glycine supplementation on top of AAFCO-compliant commercial diet is generally well-tolerated but is not currently supported by companion-animal clinical evidence at the level required for routine recommendation. Veterinary-supervised glycine supplementation may be appropriate in specific therapeutic contexts (chronic kidney disease, post-surgical recovery, glutathione-deficient oxidative stress states) under professional guidance.
What to do if you bought affected product
Pet owners can manage glycine adequacy through several practical approaches: (1) most healthy adult pets on AAFCO-compliant commercial diets receive adequate glycine through the combination of dietary protein content and endogenous synthesis from serine and threonine; the conditional-essentiality framework is more relevant for chronic disease, post-surgical recovery, and senior multi-comorbidity contexts than for routine maintenance; (2) for pets with chronic kidney disease, hepatic disease, chronic inflammation, or post-surgical recovery, prefer animal-protein-anchored formulations (named-meat-anchored with collagen-rich organ meat or connective tissue inclusion); veterinary therapeutic diets for these conditions typically have implicit glycine calibration through animal-protein anchor selection; (3) bone broth as a complement to a balanced commercial diet is reasonable and well-tolerated; bone broth as an anchor of a homemade diet without nutritionist supervision is risky and falls under the broader homemade-diet framework rather than the glycine-specific framework; (4) do not over-supplement glycine on AAFCO-compliant commercial diet for routine maintenance without veterinary indication; pharmacologic-dose glycine supplementation is a veterinary-supervised intervention in specific therapeutic contexts; (5) request brand customer-service inquiry on glycine content for premium and specialty formulations where the disclosure typically exists on technical fact sheets even when not on consumer packaging; (6) watch for chronic disease and recovery contexts where glycine adequacy may benefit clinical outcomes — chronic kidney disease, hepatic disease, inflammatory bowel disease, chemotherapy recovery, and post-surgical recovery are the typical contexts where the conditional-essentiality framework becomes load-bearing.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate glycine adequacy per our published methodology, since AAFCO does not specify a glycine minimum and brand-level disclosure of glycine content is essentially absent. The conditional-essentiality framework is emerging in companion-animal nutrition through research by Wolfgang Bauer at UC Davis and others; future rubric extension under consideration: brands publishing glycine specification with collagen-anchored ingredient inclusion would receive scoring credit for senior, growth, and recovery positioning; veterinary therapeutic diets for chronic kidney disease and hepatic disease typically have implicit glycine calibration. For now, our recommendation: assume AAFCO-compliant commercial diets meet glycine requirements adequately for healthy adult pets through endogenous synthesis and dietary protein content; for chronic disease, post-surgical recovery, and senior multi-comorbidity contexts, prefer animal-protein-anchored formulations with collagen-rich organ meat or connective tissue inclusion, or work with your veterinarian on therapeutic diet selection where glycine adequacy is implicitly calibrated.